ヒト上皮成長因子の世界市場レポート2025年

ヒト上皮成長因子市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.0％で、33億7,000万米ドルに成長します。予測期間中の成長は、再生医療や創傷治癒用途への需要の高まり、慢性皮膚疾患や傷害の有病率の増加、hEGFを含むアンチエイジングやスキンケア製品への意識の高まり、バイオテクノロジー研究開発への投資の拡大、個別化医療や標的療法の採用の増加などに起因すると考えられます。この時期の主要動向としては、組換えDNA技術の進歩、hEGFの安定性と有効性を高めるタンパク質工学の開発、ナノテクノロジーの統合、バイオプロセス技術の革新、細胞培養技術の進歩などが挙げられます。

個別化医療の採用拡大が、ヒト上皮成長因子市場の今後の成長を牽引すると予想されます。個別化医療とは、個人の遺伝子プロファイル、ライフスタイル、環境に基づいて治療をカスタマイズし、より正確で効果的な治療を提供するヘルスケア手法です。個別化医療の台頭は、ゲノム技術の進歩に後押しされています。ゲノム技術の進歩により、個々の遺伝子プロファイルをより早く、より安価に、より正確に同定し、オーダーメイドの治療を行うことができるようになりました。HER2は、医師がHER2タンパク質の過剰発現によって腫瘍を分類することを可能にし、転帰を改善し不必要な副作用を最小限に抑える標的治療の選択を支援することによって、個別化医療をサポートしています。例えば、米国を拠点とする専門家会員組織である個別化医療連合（Personalized Medicine Coalition）は、2022年には新たに12種類の個別化治療が承認され、これは新たに承認された治療全体の約34%に相当すると報告しています。その結果、個別化医療の利用拡大がヒト上皮成長因子市場の成長を後押ししています。

臨床検査数の増加が、今後のヒト上皮成長因子市場の成長を牽引すると予想されます。臨床検査とは、医療的治療や介入の安全性、有効性、副作用を評価するためのヒトを対象とした調査研究です。臨床検査の増加は、安全性と有効性の徹底的な検査を必要とする個別化された革新的な治療法に対する需要の高まりに後押しされています。ヒト上皮成長因子（hEGF）は、細胞増殖と組織修復を促進することで臨床検査をサポートし、創傷治癒や皮膚再生、関連疾患の治療評価を容易にします。例えば、ロンドンを拠点とする産業団体である英国製薬工業協会（Association of the British Pharmaceutical Industry）は2023年11月、英国における産業臨床検査の年間募集人数が15％増加し、2021～22年の3万6,722人から2022～23年には4万2,088人に増加すると報告しています。このように、臨床検査の成長がヒト上皮成長因子市場の拡大を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のヒト上皮成長因子：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヒト上皮成長因子市場：成長率分析
• 世界のヒト上皮成長因子市場の実績：規模と成長、2019～2024年
• 世界のヒト上皮成長因子市場の予測：規模と成長、2024～2029年、2034年
• 世界のヒト上皮成長因子：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のヒト上皮成長因子市場：製品タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 組換えヒト上皮成長因子
• 天然ヒト上皮成長因子
• 世界のヒト上皮成長因子市場配合別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射
• 局所
• 経口
• 世界のヒト上皮成長因子市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 直接販売
• オンライン薬局
• 小売薬局
• 病院薬局
• 専門クリニック
• 世界のヒト上皮成長因子市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮膚科
• 腫瘍学
• 眼科
• 傷の治癒
• 美容整形
• 世界のヒト上皮成長因子市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 研究機関
• その他
• 世界のヒト上皮成長因子市場、組換えヒト上皮成長因子のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 注射液
• 腫瘍治療
• 目薬
• 創傷治癒剤
• 世界のヒト上皮成長因子市場、天然ヒト上皮成長因子のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 血漿由来製品
• 初乳ベースの製品
• 羊水由来製品
• 唾液由来製剤

第7章 地域別・国別分析

• 世界のヒト上皮成長因子市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のヒト上皮成長因子市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒト上皮成長因子市場：競合情勢
• ヒト上皮成長因子市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson Services Inc
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Bayer AG

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline Plc
• Amgen Inc.
• Lonza Group AG
• STEMCELL Technologies
• Abcam plc.
• BioLegend Inc.
• Bharat BIoTech International Limited
• RayBIoTech Inc.
• Enzo Life Sciences Inc.
• Neocutis S.A
• Proteintech Group Inc.
• Creative BioMart Co. Ltd.
• Abbkine Scientific Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• ヒト上皮成長因子市場、2029年：新たな機会を提供する国
• ヒト上皮成長因子市場、2029年：新たな機会を提供するセグメント
• ヒト上皮成長因子市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Human epidermal growth factor (EGF) is a protein that promotes cell growth, proliferation, and differentiation by binding to the epidermal growth factor receptor (EGFR). It aids in accelerating wound healing by stimulating the migration and proliferation of skin cells like keratinocytes and fibroblasts, which are crucial for closing wounds and rebuilding tissue.

The main types of human epidermal growth factor products include recombinant human epidermal growth factor and natural human epidermal growth factor. Recombinant human epidermal growth factor (rhEGF) is a bioengineered protein created to stimulate cell growth and support tissue repair. It is available in various forms, such as injectable, topical, and oral. These products are distributed through multiple channels including direct sales, online pharmacies, retail pharmacies, hospital pharmacies, and specialty clinics. Key application areas cover dermatology, oncology, ophthalmology, wound healing, and cosmetic procedures. They are utilized by a range of end-users including hospitals, clinics, research institutes, and other healthcare facilities.

The human epidermal growth factor market research report is one of a series of new reports from The Business Research Company that provides human epidermal growth factor market statistics, including the human epidermal growth factor industry's global market size, regional shares, competitors with the human epidermal growth factor market share, detailed human epidermal growth factor market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor market. This human epidermal growth factor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human epidermal growth factor market size has grown strongly in recent years. It will grow from $2.18 billion in 2024 to $2.39 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the expanding geriatric population susceptible to skin-related disorders, increased government support and funding for biopharmaceutical innovations, a rising prevalence of diabetes resulting in more chronic wound cases, enhanced collaborations between pharmaceutical companies and research institutes, and a growing consumer preference for non-invasive skincare solutions.

The human epidermal growth factor market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth during the forecast period can be attributed to the rising demand for regenerative medicine and wound healing applications, increasing prevalence of chronic skin conditions and injuries, growing awareness of anti-aging and skincare products containing hEGF, expanding investment in biotechnology research and development, and the increasing adoption of personalized medicine and targeted therapies. Key trends in this period include advancements in recombinant DNA technology, developments in protein engineering that enhance hEGF stability and efficacy, integration of nanotechnology, innovations in bioprocessing techniques, and progress in cell culture technology.

The increasing adoption of personalized medicine is expected to drive the growth of the human epidermal growth factor market moving forward. Personalized medicine is a healthcare approach that customizes medical treatment based on an individual's genetic profile, lifestyle, and environment to provide more precise and effective care. The rise in personalized medicine is fueled by advances in genomic technologies, which allow faster, more affordable, and more accurate identification of individual genetic profiles for tailored treatments. HER2 supports personalized medicine by enabling physicians to classify tumors according to HER2 protein overexpression, helping select targeted therapies that improve outcomes and minimize unnecessary side effects. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2022, 12 new personalized medicines were approved, representing about 34% of all newly approved therapies-a significant increase from previous years. Consequently, the growing use of personalized medicine is propelling the growth of the human epidermal growth factor market.

The rising number of clinical trials is expected to drive the growth of the human epidermal growth factor market in the future. Clinical trials are research studies involving human participants to assess the safety, effectiveness, and side effects of medical treatments or interventions. The increase in clinical trials is fueled by the growing demand for personalized and innovative therapies that require thorough testing for safety and efficacy. Human epidermal growth factor (hEGF) supports clinical trials by promoting cell growth and tissue repair, facilitating the evaluation of treatments for wound healing, skin regeneration, and related conditions. For example, in November 2023, the Association of the British Pharmaceutical Industry, a London-based trade association, reported a 15% increase in annual recruitment for industry clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. Thus, the growth in clinical trials is propelling the expansion of the human epidermal growth factor market.

Leading companies in the human epidermal growth factor market are focusing on technological innovations such as AI-powered immunohistochemistry (IHC) scoring solutions to enhance the accuracy, speed, and consistency of biomarker detection and cancer diagnostics. An AI-powered IHC scoring solution uses artificial intelligence algorithms to automatically analyze and quantify protein expression in tissue samples stained via IHC, improving precision, reproducibility, and efficiency in diagnostic pathology. For example, in September 2023, Ibex Medical Analytics, an Israel-based company, introduced Ibex Breast HER2. This technology improves the precision and consistency of HER2 biomarker scoring in breast cancer, particularly in difficult HER2-low cases, enabling optimized treatment plans and better patient outcomes. Its key benefits include highly accurate, reproducible, and efficient HER2 IHC scoring, assisting pathologists in making confident, objective decisions for selecting targeted therapies.

Major players in the human epidermal growth factor market are Pfizer Inc., Johnson & Johnson Services Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., Lonza Group AG, STEMCELL Technologies, Abcam plc., BioLegend Inc., Bharat Biotech International Limited, RayBiotech Inc., Enzo Life Sciences Inc., Neocutis S.A, Proteintech Group Inc., Creative BioMart Co. Ltd., Abbkine Scientific Co. Ltd.

North America was the largest region in the human epidermal growth factor market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human epidermal growth factor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human epidermal growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human epidermal growth factor market consists of sales of skincare serums and creams, wound-healing gels and ointments, and hair growth treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Epidermal Growth Factor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human epidermal growth factor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human epidermal growth factor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human epidermal growth factor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Recombinant Human Epidermal Growth Factor; Natural Human Epidermal Growth Factor
• 2) By Formulation: Injectable Form; Topical Form; Oral Form
• 3) By Distribution Channel: Direct Sales; Online Pharmacies; Retail Pharmaceis; Hospital Pharmacies; Specialty Clinics
• 4) By Application: Dermatology; Oncology; Opthalmology; Wound Healing; Cosmetic Procedures
• 5) By End-User: Hospitals; Clincs; Research Institutes; Other End Users
• Subsegments:
• 1) By Recombinant Human Epidermal Growth Factor: Injectable solutions; Oncology therapeutics; Eye drops; Wound healing agents
• 2) By Natural Human Epidermal Growth Factor: Plasma-derived products; Colostrum-based products; Amniotic fluid-derived products; Salivary-derived formulations
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Epidermal Growth Factor Market Characteristics

3. Human Epidermal Growth Factor Market Trends And Strategies

4. Human Epidermal Growth Factor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Epidermal Growth Factor Growth Analysis And Strategic Analysis Framework

• 5.1. Global Human Epidermal Growth Factor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Human Epidermal Growth Factor Market Growth Rate Analysis
• 5.4. Global Human Epidermal Growth Factor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Human Epidermal Growth Factor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Human Epidermal Growth Factor Total Addressable Market (TAM)

6. Human Epidermal Growth Factor Market Segmentation

• 6.1. Global Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Human Epidermal Growth Factor
• Natural Human Epidermal Growth Factor
• 6.2. Global Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Form
• Topical Form
• Oral Form
• 6.3. Global Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies
• Specialty Clinics
• 6.4. Global Human Epidermal Growth Factor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dermatology
• Oncology
• Opthalmology
• Wound Healing
• Cosmetic Procedures
• 6.5. Global Human Epidermal Growth Factor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Institutes
• Other End Users
• 6.6. Global Human Epidermal Growth Factor Market, Sub-Segmentation Of Recombinant Human Epidermal Growth Factor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Solutions
• Oncology Therapeutics
• Eye Drops
• Wound Healing Agents
• 6.7. Global Human Epidermal Growth Factor Market, Sub-Segmentation Of Natural Human Epidermal Growth Factor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma-Derived Products
• Colostrum-Based Products
• Amniotic Fluid-Derived Products
• Salivary-Derived Formulations

7. Human Epidermal Growth Factor Market Regional And Country Analysis

• 7.1. Global Human Epidermal Growth Factor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Human Epidermal Growth Factor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Epidermal Growth Factor Market

• 8.1. Asia-Pacific Human Epidermal Growth Factor Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Epidermal Growth Factor Market

• 9.1. China Human Epidermal Growth Factor Market Overview
• 9.2. China Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Epidermal Growth Factor Market

• 10.1. India Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Epidermal Growth Factor Market

• 11.1. Japan Human Epidermal Growth Factor Market Overview
• 11.2. Japan Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Epidermal Growth Factor Market

• 12.1. Australia Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Epidermal Growth Factor Market

• 13.1. Indonesia Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Epidermal Growth Factor Market

• 14.1. South Korea Human Epidermal Growth Factor Market Overview
• 14.2. South Korea Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Epidermal Growth Factor Market

• 15.1. Western Europe Human Epidermal Growth Factor Market Overview
• 15.2. Western Europe Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Epidermal Growth Factor Market

• 16.1. UK Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Epidermal Growth Factor Market

• 17.1. Germany Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Epidermal Growth Factor Market

• 18.1. France Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Epidermal Growth Factor Market

• 19.1. Italy Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Epidermal Growth Factor Market

• 20.1. Spain Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Epidermal Growth Factor Market

• 21.1. Eastern Europe Human Epidermal Growth Factor Market Overview
• 21.2. Eastern Europe Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Epidermal Growth Factor Market

• 22.1. Russia Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Epidermal Growth Factor Market

• 23.1. North America Human Epidermal Growth Factor Market Overview
• 23.2. North America Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Epidermal Growth Factor Market

• 24.1. USA Human Epidermal Growth Factor Market Overview
• 24.2. USA Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Epidermal Growth Factor Market

• 25.1. Canada Human Epidermal Growth Factor Market Overview
• 25.2. Canada Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Epidermal Growth Factor Market

• 26.1. South America Human Epidermal Growth Factor Market Overview
• 26.2. South America Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Epidermal Growth Factor Market

• 27.1. Brazil Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Epidermal Growth Factor Market

• 28.1. Middle East Human Epidermal Growth Factor Market Overview
• 28.2. Middle East Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Epidermal Growth Factor Market

• 29.1. Africa Human Epidermal Growth Factor Market Overview
• 29.2. Africa Human Epidermal Growth Factor Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Human Epidermal Growth Factor Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Human Epidermal Growth Factor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Epidermal Growth Factor Market Competitive Landscape And Company Profiles

• 30.1. Human Epidermal Growth Factor Market Competitive Landscape
• 30.2. Human Epidermal Growth Factor Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Human Epidermal Growth Factor Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline Plc
• 31.4. Amgen Inc.
• 31.5. Lonza Group AG
• 31.6. STEMCELL Technologies
• 31.7. Abcam plc.
• 31.8. BioLegend Inc.
• 31.9. Bharat Biotech International Limited
• 31.10. RayBiotech Inc.
• 31.11. Enzo Life Sciences Inc.
• 31.12. Neocutis S.A
• 31.13. Proteintech Group Inc.
• 31.14. Creative BioMart Co. Ltd.
• 31.15. Abbkine Scientific Co. Ltd.

32. Global Human Epidermal Growth Factor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Epidermal Growth Factor Market

34. Recent Developments In The Human Epidermal Growth Factor Market

35. Human Epidermal Growth Factor Market High Potential Countries, Segments and Strategies

• 35.1 Human Epidermal Growth Factor Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Human Epidermal Growth Factor Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Human Epidermal Growth Factor Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer